Shareprice
18 Apr 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022

News


October 6, 2022

Copenhagen, Denmark, 6 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Principal Investigator, Chief Surgeon Jane Skjøth-Rasmussen will be presenting the outstanding clinical data from the completed phase I/IIa trial with FG001 in patients with aggressive brain cancer undergoing surgery at the European Congress of Neurosurgery on 19 October 2022 in Belgrade, Serbia.

The excellent phase l/lla clinical data of FG001 in aggressive brain cancer will be presented by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen at the European Congress of Neurosurgery in Belgrade, facilitated by the European Association of Neurosurgical Societies (EANS).

The purpose of the trial was to investigate FG001 for intraoperative visualization of malignant glioma in patients scheduled for neurosurgery. The full abstract can be found here.

Based on the promising clinical data, FG001 is advanced into a phase IIb trial in aggressive brain cancer where the top line result is expected in H1 2023.